Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-30 @ 12:07 AM
Study NCT ID:
NCT07336732
Status:
RECRUITING
Last Update Posted:
2026-03-20
First Post:
2025-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 40}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2026-03-11', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2026-03', 'completionDateStruct': {'date': '2029-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-03-18', 'studyFirstSubmitDate': '2025-12-18', 'studyFirstSubmitQcDate': '2026-01-02', 'lastUpdatePostDateStruct': {'date': '2026-03-20', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-01-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).', 'timeFrame': 'Up to 3 years', 'description': 'In phase II，Incidence of Treatment-Emergent Adverse Events (TEAEs)'}, {'measure': 'RP3D or recommended phase 3 treatment regimen', 'timeFrame': 'Up to 3 years', 'description': 'In phase II, choose the RP3D per gained safety and efficacy data'}], 'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR)', 'timeFrame': 'Up to 3 years', 'description': 'To evaluate the Overall Response Rate (ORR) which is defined by investigator as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v1.1'}, {'measure': 'Duration of Response(DOR)', 'timeFrame': 'up to 3 years', 'description': 'DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes frst'}, {'measure': 'Disease Control Rate(DCR)', 'timeFrame': 'up to 3 years', 'description': 'The percentage of tumor patients achieving complete remission (CR), partial remission (PR), or stable disease (SD) following treatment, relative to the total number of evaluable subjects'}, {'measure': 'Progression-Free Survival(PFS)', 'timeFrame': 'up to 3 years', 'description': 'PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause whichever comes first, based on investigator review according to RECIST v1.1'}, {'measure': '6-month Progression-Free Survival Rate', 'timeFrame': 'up to 3 years', 'description': 'The proportion of subjects who did not experience disease progression or death within 6 months after receiving treatment.'}, {'measure': '6-month Overall Survival Rate', 'timeFrame': 'up to 3 years', 'description': 'The proportion of subjects who did not experience death within 6 months after receiving treatment.'}, {'measure': 'Assess the PK characteristics of Andamertinib', 'timeFrame': 'On cycle1of day 1and cycle3of day1, samples were collected within 2 hours prior to dosing and 4 hours post-dosing,On Day 1of Cycle 2, Cycle 5, Cycle 7, and all subsequent odd-numbered cycles collected within 2hours prior to dosing(each cycle is 21days)', 'description': 'Plasma concentration of Andamertinib'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Non-Small-Cell Lung Cance', 'EGFR', 'PACC', 'L861Q', 'Lung Cancer', 'EGFR ex20ins'], 'conditions': ['Non-Small-Cell Lung Cancer']}, 'descriptionModule': {'briefSummary': 'This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR atypical mutations. The study comprises two stages: phase II (dose-exploration stage) and phase III (pivotal study stage)', 'detailedDescription': 'This a three-stage study consist a Screening Phase (Day -28 to -1), a Treatment Phase (until treatment discontinuation), and a Follow-up Phase (including end of treatment visit (EOT),end of study visit(EOS), safety follow-up and survival follow-up).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age ≥18 years at the time of ICF signing.\n2. Histologically or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC).\n3. Confirmed EGFR atypical mutation.\n4. No prior systemic therapy for locally advanced or metastatic NSCLC.\n5. At least one measurable lesion as defined by RECIST v1.1.\n6. ECOG PS ≤1.\n7. Life expectancy≥12 weeks.\n8. Adequate organ function confirmed within 7 days prior to the first dose of study treatment\n9. Female participants must use adequate contraceptive measures during study participation and for 90 days after the last dose of study treatment and must not be breastfeeding; female subjects not of childbearing potential must meet at least one of the following criteria at screening: Postmenopausal status; Documentation of irreversible surgical sterilization.\n10. Non-sterilized males: Abstinence or contraception use; No sperm donation.\n11. Willing and able to provide signed ICF and to comply with all requirements and restrictions listed in the ICF and this study protocol.\n\nExclusion Criteria:\n\n1. Presence of specific genetic alterations for which approved targeted therapies are available.\n2. Recent participation (within 28 days) in another interventional clinical trial.\n3. Major surgery within 28 days prior to study entry or planned during the study period.\n4. Recent use of anti-tumor traditional proprietary medicine or local anti-tumor therapy.\n5. Need for specific concomitant medications (e.g., metformin) that cannot be paused during the study.\n6. History of another active malignancy within the past 5 years (except for specific cured cancers).\n7. Toxicities from prior therapy have not recovered to acceptable levels.\n8. Presence of symptomatic or uncontrolled brain metastases, carcinomatous meningitis, or spinal cord compression.\n9. Symptomatic and uncontrolled third-space fluid accumulations (e.g., pleural effusion, ascites).\n10. Severe cardiovascular/cerebrovascular disease or risk factors (e.g., heart failure, history of myocardial infarction, QT prolongation, uncontrolled hypertension, etc.).\n11. History or presence of interstitial lung disease, or drug/radiation-related pneumonitis.\n12. Active autoimmune or inflammatory diseases.\n13. Active, uncontrolled infection (including HBV, HCV, HIV, syphilis, tuberculosis, etc.).\n14. Gastrointestinal disorders or surgery affecting drug ingestion or absorption.\n15. Active keratitis or ulcerative keratitis.\n16. History of hypersensitivity to the study drug, its analogs, or chemotherapy drugs (pemetrexed/platinum agents).\n17. Recent administration (within 30 days) of a live attenuated vaccine.\n18. Psychiatric disorders or substance abuse potentially affecting compliance.\n19. Any other condition deemed by the investigator as unsuitable for study participation.'}, 'identificationModule': {'nctId': 'NCT07336732', 'acronym': 'KANNON-5', 'briefTitle': 'Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations', 'organization': {'class': 'INDUSTRY', 'fullName': 'Avistone Biotechnology Co., Ltd.'}, 'officialTitle': 'An Open-label, Randomized, Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harboring Atypical EGFR Mutations Who Have Not Received Prior Systematic Therapy', 'orgStudyIdInfo': {'id': 'PLB1004-II/III-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy', 'description': 'PLB1004, oral, QD Platinum-based chemotherapy， injection, once every 21-day', 'interventionNames': ['Drug: PLB1004']}], 'interventions': [{'name': 'PLB1004', 'type': 'DRUG', 'description': 'Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy', 'armGroupLabels': ['Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Guangzhou', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'LI Zhang', 'role': 'CONTACT', 'email': 'zhangli@sysucc.org.cn', 'phone': '+86 13948537070'}], 'facility': 'Sun Yat-Sen University Cancer Center', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}], 'centralContacts': [{'name': 'Haimeng Li', 'role': 'CONTACT', 'email': 'lihaimeng@pearlbio.cn', 'phone': '+86 17610831060'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Avistone Biotechnology Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}